Cargando…
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was develo...
Autores principales: | Heo, Sook-Kyoung, Noh, Eui-Kyu, Yu, Ho-Min, Kim, Do Kyoung, Seo, Hye Jin, Lee, Yoo Jin, Cheon, Jaekyung, Koh, Su Jin, Min, Young Joo, Choi, Yunsuk, Jo, Jae-Cheol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718665/ https://www.ncbi.nlm.nih.gov/pubmed/33276759 http://dx.doi.org/10.1186/s12885-020-07701-8 |
Ejemplares similares
-
Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
por: Heo, Sook-Kyoung, et al.
Publicado: (2022) -
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021) -
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2017) -
Author Correction: Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2021) -
Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells
por: Heo, Sook-Kyoung, et al.
Publicado: (2015)